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Enzastaurin (LY317615.HCl), a selective PKC beta inhibitor, 
suppresses human lung cancer cells in vitro and in vivo: a 
pharmacodynamic study
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Background: PKC isoforms have been implicated in human cancer 
proliferation, cell cycle progression, angiogenesis and apoptosis. 
Altered expression and phosphorylation of PKC has been demonstrated 
in several NSCLC cell lines versus normal lung epithelia cell lines. 
Enzastaurin (LY317615), a selective PKC-beta inhibitor, has been 
shown to inhibit a variety of human tumors in vitro and in vivo. In this 
report, we evaluated the effects of Enzastaurin on PKC/AKT signaling 
activation as well as its in vitro and in vivo therapeutic effects against 
human lung cancers.
Methods: Western blots were used for PKC/AKT signaling analysis. In 
vitro antigrowth effects of Enzastaurin were accessed with MTT assay. 
Athymic nude mice bearing human lung xenografts H2122 adenocar-
cinoma or H358 bronchial alveolar carcinoma (BAC) were used for in 
vivo efﬁcacy studies, in conjunction with pharmacodynamic analysis 
and in vivo imaging studies.
Results: By western blot analysis, we found that Enzastaurin signiﬁ-
cantly reduced phosphorylation of GSK3-beta (Ser9), ribosomal protein 
S6 (Ser240 /244) but not AKT (Thr308) in both NSCLC and SCLC cell 
lines. Our MTT assay showed that Enzastaurin inhibited the growth of 
14 NSCLC cell lines with average IC50 of 8.2 µM, ranging 1.5 to 20 
µM and 14 SCLC cell lines with average IC50 of 7.0 µM, ranging 3 to 
10 µM. The sensitivities toward Enzastaurin among the four different 
NSCLC histologies (adenocarcinomas, squamous, large cell carcino-
mas or bronchial alveolar carcinoma) are very similar. Using Combi-
nation-Index analysis, when Enzastaurin was combined with peme-
trexed concurrently or pemetrexed then Enzastaurin sequentially, the 
interaction is greater than additive effect. Our in vivo studies showed 
that Enzastaurin by daily BID oral gavages at 38, 75 and 150 mg/kg 
suppressed human H2122 adenocarcinomas implanted subcutaneously 
in athymic nude mice, but not in a dose-dependent manner. When 
treated orally with daily BID at 25, 35 and 75 mg/kg in a xenograft 
with more sensitive H358 BAC cell line, more impressive therapeutic 
effects at 35 mg/kg were achieved but again not in a dose-dependent 
manner. In conjunction with efﬁcacy of Enzastaurin in tumor bearing 
nude mice, plasma pharmacokinetics were studied on day 3, 10 or 21 
following the start of dosing. The mean plasma Enzastaurin levels for 
these days were approximately 1045±80 ng/mL for 38 mg/kg dose; 
1473±436 ng/mL for 75 mg/kg dose; 3435±798 ng/mL for 150 mg/kg 
respectively. Real time in vivo pharmacodynamics of Enzastaurin was 
analyzed simultaneously using in vivo ﬂuorescent imaging method in 
tumor bearing live animals. Enzastaurin has unique ﬂuorescent proper-
ties which emits strongly with red ﬂuorescent spectrum giving good tis-
sue penetration when excited with appropriate wavelength. Our in vivo 
imaging showed the presence of Enzastaurin within the tumor mass and 
in plasma, in consistent with the observed pharmacodynamic data and 
supporting the therapeutic effects of Enzastaurin against human lung 
xenografts. 
Conclusions: Our preclinical data provided strong evidence that Enza-
staurin may be effective for the treatment of human lung cancers. 
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Determining optimal respiratory gating parameters for passively 
scattered synchrotron based proton irradiation
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Purpose: Greater normal tissue spearing can be potentially realized 
by taking advantage of the physical characteristics of particle beams 
(proton or carbon). Respiratory gated delivery of such particle beams 
offers the advantages through margin reduction and dose escalation for 
respiratory mobile tumors in the lung. Unfortunately, for synchrotron-
based proton irradiation, it may not be efﬁcient. We have determined 
the optimal respiratory gating parameters for passively scattered proton 
irradiation on a synchrotron through a simulation study.
Method and Materials: An in-house software program was developed 
to investigate the interaction of the respiratory gating intervals with 
different synchrotron magnet excitation cycle patterns. Test data was 
obtained by using the recorded respiratory trace of 94 patients who 
underwent 4DCT. A typical magnet excitation cycle, Tcyc consists of 
proton acceleration, ﬂat top and deceleration periods. Proton beam 
delivery occurs only during the ﬂat top portion of each such excitation 
cycle. Respiratory gating was simulated at expiration for a 30% duty 
cycle around peak exhalation. The time required to deliver 100 Monitor 
Unites (MUs) was estimated for the following scenarios: (a) Ungated 
irradiation with Tcyc set to the minimum value (2.7sec) and (b) Gated 
irradiation with Tcyc set to (i) the minimum value, (ii) approximately 
equal each patient’s average respiratory cycle, and (iii) a variable value 
according to each individual respiratory cycle. Overall treatment time 
and efﬁciency of treatment delivery were studied in each case.
Results: Average times required to deliver 100 MUs were 1.1 minutes 
for ungated irradiation; and 3.7 (1.7 - 6.0), 3.2 (1.6 - 7.1), 2.3 (1.4 - 3.1) 
minutes respectively for gated irradiations at various scenarios men-
tioned above. For gated irradiation, variable Tcyc mode of operation 
yielded least overall treatment time and greatest efﬁciency of proton 
beam delivery.
Conclusion: Respiratory gated passively scattered proton delivery 
using a synchrotron-based system is feasible without signiﬁcantly 
increasing treatment time. Based on above results, variable Tcyc mode 
of operation offered least overall treatment time and greatest efﬁciency 
for respiratory gated irradiation.
